bioRxivMolecular BiologyPreprint
AAV and lentiviral transduction in Duchenne muscular dystrophy cardiomyocytes activate cell stress responses
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked muscle wasting disorder marked by lack of dystrophin expression. Symptoms include loss of ambulation, respiratory problems, and cardiac complications with heart failure being the leading cause of death. Dystrophin transduces force from the actin cytoskeleton to the extracellular matrix to protect cells during muscle contraction. Restoration of dystrophin expression by gene transfer holds promise in addressing the root cause of disease. We compared the changes to transcriptional profiles after gene transfer by adeno-associated virus or lentivirus to examine whether viral treatment alone impacts cell homeostasis. We delivered GFP to cardiomyocytes differentiated from induced pluripotent stem cells (iPSCs) with DMD mutations. Global transcriptional profiling revealed a downregulation of metabolic genes after lentiviral transduction compared to untreated controls. In both AAV and lentivirus-treated DMD iPSC-cardiomyocytes, we observed an activation of the p53 DNA damage response in addition to a downregulation of cell cycle genes, suggesting stress-induced G2/M checkpoint arrest following viral delivery. These findings demonstrate that gene therapy mediated by viral vectors activates cell stress pathways. Interventions to mitigate these stress responses may be necessary for safe and effective gene transfer in diseased cells.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potential limitations of micro-dystrophin gene therapy for Duchenne muscular dystrophy
C. C. Hart, Y. i. Lee, … L. Sweeney·bioRxiv·Oct 2, 2022
- Dual S100A1 and ARC gene therapy as a treatment for DMD cardiomyopathy
David W. Hammers, Cora C. Hart, … Hugh Lee Sweeney·bioRxiv·Aug 23, 2025
- TRF2 rescues telomere attrition and prolongs cell survival in Duchenne muscular dystrophy cardiomyocytes derived from human iPSCs
A. Eguchi, S. I. Torres-Bigio, … H. M. Blau·bioRxiv·Jan 10, 2022
- Phenotypic Switching of Vascular Smooth Muscle Cells in Duchenne Muscular Dystrophy
- Gene Therapy for Cardiomyopathy associated with Duchenne Muscular Dystrophy in a Pig Model
A. Baehr, P. Hoppmann, … C. Kupatt·bioRxiv·Oct 2, 2023
- Disease exacerbation by fibroblast inclusion in Duchenne Muscular Dystrophy MYOrganoids reveals limitations of microdystrophin therapeutic efficacy
L. Palmieri, L. Pili, … S. Albini·bioRxiv·Jul 26, 2023